Clinical Trial Update: SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SBRT alone or followed by Niraparib for recurrent ovarian cancer with oligometastases or oligoprogression after PARP inhibitor therapy;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Zejula (Niraparib)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Ovarian Cancer Recurrent | Phase 2 | Status: RECRUITING